Case report: Identification of acute promyelocytic leukemia during osimertinib resistance followed by granulocyte colony-stimulating factor and pembrolizumab.

Tian, Huohuan; Yang, Linhui; Hou, Wang; Wu, Yu; Dai, Yang; Yu, Jiang; Liu, Dan

Tian, Huohuan; Yang, Linhui; Hou, Wang; Wu, Yu; Dai, Yang; Yu, Jiang; Liu, Dan.

Afiliación

Tian H; Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yang L; Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Hou W; Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Wu Y; Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Dai Y; Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yu J; Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Liu D; Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Front Oncol ; 12: 1032225, 2022.

Article en En | MEDLINE | ID: mdl-36713543

Palabras clave

granulocyte colony-stimulating factor; lung cancer; osimertinib; pembrolizumab; therapy-related acute promyelocytic leukemia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google